000			02077 a2200541 4500
005			20250517081103.0
264		0	_c20160706
008			201607s 0 0 eng d
022			_a1532-1967
024	7		_a10.1016/j.ctrv.2016.02.001 _2doi
040			_aNLM _beng _cNLM
100	1		_aSpain, Lavinia
245	0	0	_aManagement of toxicities of immune checkpoint inhibitors. _h[electronic resource]
260			_bCancer treatment reviews _cMar 2016
300			_a51-60 p. _bdigital
500			_aPublication Type: Journal Article; Review
650	0	4	_aAdrenal Cortex Hormones _xtherapeutic use
650	0	4	_aAntibodies, Monoclonal _xadverse effects
650	0	4	_aAntibodies, Monoclonal, Humanized _xadverse effects
650	0	4	_aAntilymphocyte Serum _xtherapeutic use
650	0	4	_aAntineoplastic Agents _xadverse effects
650	0	4	_aCTLA-4 Antigen _xantagonists & inhibitors
650	0	4	_aCarcinoma, Renal Cell _xdrug therapy
650	0	4	_aChemical and Drug Induced Liver Injury _xdrug therapy
650	0	4	_aColitis _xchemically induced
650	0	4	_aCyclosporine _xtherapeutic use
650	0	4	_aDiarrhea _xchemically induced
650	0	4	_aDrug Eruptions _xdrug therapy
650	0	4	_aHumans
650	0	4	_aImmunosuppressive Agents _xtherapeutic use
650	0	4	_aInfliximab _xtherapeutic use
650	0	4	_aIpilimumab
650	0	4	_aKidney Neoplasms _xdrug therapy
650	0	4	_aLung Neoplasms _xdrug therapy
650	0	4	_aMelanoma _xdrug therapy
650	0	4	_aMycophenolic Acid _xanalogs & derivatives
650	0	4	_aNeoplasms _xdrug therapy
650	0	4	_aNivolumab
650	0	4	_aPituitary Diseases _xchemically induced
650	0	4	_aProgrammed Cell Death 1 Receptor _xantagonists & inhibitors
650	0	4	_aSkin Neoplasms _xdrug therapy
650	0	4	_aTacrolimus _xtherapeutic use
650	0	4	_aThyroiditis _xchemically induced
700	1		_aDiem, Stefan
700	1		_aLarkin, James
773	0		_tCancer treatment reviews _gvol. 44 _gp. 51-60
856	4	0	_uhttps://doi.org/10.1016/j.ctrv.2016.02.001 _zAvailable from publisher's website
999			_c25730944 _d25730944